Table 1. Characteristics of 10,383 Myocardial Infarction Patients Discharged Alive.
| Variable | Total | Anterior MI | Other MI | P-value |
| N = 10,383 | N = 2,942 | N = 7,441 | ||
| Patient Demographics | ||||
| Age | 66.46±13.51 | 65.52±13.75 | 66.84±13.39 | <.001 |
| Male | 6,805 (65.5%) | 1,976 (67.2%) | 4,829 (64.9%) | 0.03 |
| Past Medical History | ||||
| Diabetes mellitus | 2,621 (25.2%) | 707 (24.0%) | 1,914 (25.7%) | 0.07 |
| Myocardial infarction | 2,333 (22.5%) | 595 (20.2%) | 1,738 (23.4%) | <.001 |
| Congestive heart failure | 418 (4.0%) | 120 (4.1%) | 298 (4.0%) | 0.86 |
| Hypertension | 4,692 (45.2%) | 1,291 (43.9%) | 3,401 (45.7%) | 0.09 |
| Previous smoker | 2,569 (24.7%) | 674 (22.9%) | 1,895 (25.5%) | 0.007 |
| Previous atrial fibrillation | 122 (1.2%) | 26 (0.9%) | 96 (1.3%) | 0.08 |
| Previous ischemic stroke | 133 (1.3%) | 33 (1.1%) | 100 (1.3%) | 0.36 |
| In Hospital Findings & Procedures | ||||
| Peak creatine kinase (CK) >2 times the upper limit of normal | 6,293 (60.6%) | 1,966 (66.8%) | 4,327 (58.2%) | <.001 |
| Killip class ≥3 | 248 (2.4%) | 82 (2.8%) | 166 (2.2%) | 0.09 |
| LV dysfunction | 1,461 (14.1%) | 679 (23.1%) | 782 (10.5%) | <.001 |
| LV aneurysm, thrombus, or ventricular septal defect (VSD) | 226 (2.2%) | 139 (4.7%) | 87 (1.2%) | <.001 |
| ST elevation on any lead groups | 4,979 (48.0%) | 2,474 (84.1%) | 2,505 (33.7%) | <.001 |
| Reperfusion therapy | 3,414 (32.9%) | 1,419 (48.2%) | 1,995 (26.8%) | <.001 |
| Discharge systolic blood pressure | 120.42±19.68 | 118.01±19.39 | 121.36±19.65 | <.001 |
| Discharge diastolic blood pressure | 67.89±11.62 | 67.33±12.07 | 68.11±11.43 | 0.002 |
| In-hospital atrial fibrillation | 620 (6.0%) | 171 (5.8%) | 449 (6.0%) | 0.67 |
| In-hospital ischemic stroke | 20 (0.2%) | 7 (0.2%) | 13 (0.2%) | 0.51 |
| Discharge Medications | ||||
| ACE inhibitors | 5,578 (53.7%) | 1,745 (59.3%) | 3,833 (51.5%) | <.001 |
| Angiotensin II receptor blocker (ARB) | 216 (2.1%) | 67 (2.3%) | 149 (2.0%) | 0.38 |
| Antiarrhythmics or digoxin | 1,232 (11.9%) | 364 (12.4%) | 868 (11.7%) | 0.32 |
| Anticoagulants | 1558 (15.0%) | 640 (21.8%) | 918 (12.3%) | <.001 |
| Aspirin | 7,877 (75.9%) | 2,137 (72.6%) | 5,740 (77.1%) | <.001 |
| Beta-adrenergic antagonists | 7,021 (67.6%) | 2,026 (68.9%) | 4,995 (67.1%) | 0.09 |
| Calcium antagonists | 2,713 (26.1%) | 645 (21.9%) | 2,068 (27.8%) | <.001 |
| Clopidogrel | 529 (5.1%) | 173 (5.9%) | 356 (4.8%) | 0.02 |
| Diuretics | 2,593 (25.0%) | 725 (24.6%) | 1,868 (25.1%) | 0.63 |
| Low molecular weight heparin (LMWH) | 237 (2.3%) | 60 (2.0%) | 177 (2.4%) | 0.30 |
| Nitrates | 4,346 (41.9%) | 1,102 (37.5%) | 3,244 (43.6%) | <.001 |
| Statins | 3,453 (33.3%) | 952 (32.4%) | 2,501 (33.6%) | 0.22 |
| Warfarin | 870 (8.4%) | 400 (13.6%) | 470 (6.3%) | <.001 |
Data are reported as number (percentage) of patients or mean ± standard deviation (SD) value unless otherwise specified.